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Abstract
Background: Pathogenic variants in SCN1A cause variable epilepsy disorders with 
different disease severities. We here investigate whether common variation in the 
promoter region of the unaffected SCN1A allele could reduce normal expression, 
leading to a decreased residual function of Nav1.1, and therefore to more severe 
clinical outcomes in patients affected by pathogenic SCN1A variants.
Methods: Five different SCN1A promoter‐haplotypes were functionally assessed in 
SH‐SY5Y cells using Firefly and Renilla luciferase assays. The SCN1A promoter 
region was analyzed in a cohort of 143 participants with SCN1A pathogenic vari-
ants. Differences in clinical features and outcomes between participants with and 
without common variants in the SCN1A promoter‐region of their unaffected allele 
were investigated.
Results: All non‐wildtype haplotypes showed a significant reduction in luciferase 
expression, compared to the wildtype promoter‐region (65%–80%, p  =  0.039–
0.0023). No statistically significant differences in clinical outcomes were observed 
between patients with and without common promoter variants. However, patients 
with a wildtype promoter‐haplotype on their unaffected SCN1A allele showed a non-
significant trend for milder phenotypes.
Conclusion: The nonsignificant observed trends in our study warrant replication 
studies in larger cohorts to explore the potential modifying role of these common 
SCN1A promoter‐haplotypes.
K E Y W O R D S
Dravet, GEFS+, promoter, SCN1A, variable expression
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1 |  INTRODUCTION
Dravet syndrome is one of the most well‐known genetic epi-
lepsy syndromes. The main characteristics of the disease are 
early onset intractable epileptic seizures and a delayed psy-
chomotor development that results in mild to severe intellec-
tual disability (ID). Furthermore, many patients experience 
walking difficulties and/or behavioral problems (Brunklaus, 
Ellis, Reavey, Forbes, & Zuberi, 2012; Dravet, 1978, 2011; 
Gitiaux et al., 2016; Rilstone, Coelho, Minassian, & Andrade, 
2012). Mutations in the SCN1A gene (OMIM 182389) are the 
cause of disease and detected in the majority of Dravet syn-
drome patients (Parihar & Ganesh, 2013). SCN1A encodes 
for the α‐subunit of a neuronal sodium channel, Nav1.1. The 
main disease mechanism in SCN1A‐related Dravet syndrome 
is haploinsufficiency, caused by complete or partial loss of 
function of the channel, which leads to disturbances in neuro-
nal excitability (Catterall, Kalume, & Oakley, 2010; Escayg 
& Goldin, 2010).
Pathogenic variants in SCN1A are also found in patients 
with much milder phenotypes, such as Genetic Epilepsy 
Febrile Seizures Plus (GEFS+) syndrome or febrile seizures 
only (Escayg et al., 2000). The association of SCN1A with 
multiple phenotypes may be partly explained by the varying 
effects of different pathogenic variants: variants that cause a 
complete loss of function (LoF) of the channel are virtually 
always associated with severe phenotypes, whereas variants 
that cause milder disturbances are usually found in milder 
phenotypes (Meng et al., 2015). However, this does not fully 
explain the variability that is observed in SCN1A related 
phenotypes: varying phenotypes have been associated with 
the exact same variant, even within families, and Dravet syn-
drome patients with similar LoF variants may show very dif-
ferent clinical outcomes (Akiyama, Kobayashi, Yoshinaga, & 
Ohtsuka, 2010; Depienne et al., 2010; Guerrini et al., 2010; 
Harkin et al., 2007; Jansen et al., 2006; Mahoney et al., 2009; 
Passamonti et al., 2015; Pineda‐Trujillo et al., 2005; Suls 
et al., 2010). Several modifying factors have already been 
proven or suggested to have an influence on these outcomes, 
such as mosaicism for the pathogenic SCN1A variants, the 
presence of variants in modifier genes and environmental 
factors such as anti‐epileptic treatment (Ceulemans, 2011; 
Depienne et al., 2010; Gennaro et al., 2006; Guerrini et al., 
1998; Lange, Gunning, et al., 2018; Lange, Koudijs, et al., 
2018; Marini, Mei, Helen Cross, & Guerrini, 2006).
Another factor that could potentially contribute to pheno-
typic variability is additional variation in the SCN1A gene 
itself. Genome‐wide association studies (GWAS) have shown 
a significant association between SCN1A and genetic gener-
alized, focal and unclassified epilepsies in general, and hip-
pocampal sclerosis and febrile seizures (Anney et al., 2014; 
Kasperavičiute et al., 2013). This observation suggests that 
common, low risk variation may affect normal function and/
or expression of SCN1A. SCN1A has at least three major 
promoters that are simultaneously active in various brain 
regions including the cerebellum, cerebral cortex, putamen, 
hippocampus, and thalamus (Dong et al., 2014; Long et al., 
2008; Nakayama et al., 2010). Promoter 1 (P1a) alone yielded 
transcription activity in a neuronal cell culture assay, though 
the activity was greatly enhanced when 5’ untranslated exons 
(UE) were added (Long et al., 2008). A total of five 5’ UEs 
of SCN1A are currently known, all of them carrying multiple 
putative transcription factor binding sites (Long et al., 2008; 
Martin, Tang, Ta, & Escayg, 2007). Adding to the complexity 
of SCN1A transcription, the 5’ untranslated region including 
the three promoters are located in a span of 75 Kb upstream 
of the first coding exon (Long et al., 2008; Martin et al., 2007) 
(Figure 1). This region has not been studied extensively in 
Dravet syndrome patients, but may harbor mutations that 
could either be the cause of their epilepsy, or include variants 
that could modify the phenotype caused by another major 
mutation in the coding region of the gene. So far, two reports 
have been published that suggested that pathogenic mutations 
in the regulatory 5’ region of SCN1A were likely the cause of 
disease in two Dravet syndrome patients, as no SCN1A cod-
ing mutations could be detected. Interestingly, the novel pro-
moter mutations were found to reduce transcription in vitro, 
increasing the likelihood of their causality (Gao et al., 2017; 
Nakayama et al., 2010). These findings stress the importance 
of the SCN1A promoter‐regions for correct functioning of the 
F I G U R E  1  Overview SCN1A 5' UTR. SCN1A has a complex 5’ UTR. Three major promoter regions (blue) and five 5’ UE (pink) are 
currently known. The half‐tick up lines indicate a promoter region with a subsequent 5’ UE which together carry consensus regions for multiple 
transcription factor binding sites and initiator elements. Transcription start sites are indicated with an arrow. Dashed lines indicate the distance to 
next element. Underlined elements indicate the remaining two 5’ UEs and the first coding exon of SCN1A (green). Figure established based on 
previous work (Dong et al., 2014; Long et al., 2008; Nakayama et al., 2010)
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Nav1.1 channel. It has previously been suggested that part of 
the 20%–30% of Dravet syndrome patients in whom no cod-
ing variants in SCN1A could be detected, harbor mutations in 
its regulatory regions (Djémié et al., 2016). However, in most 
diagnostic centers the promoter regions are not routinely se-
quenced when analyzing SCN1A, so its exact role remains 
unclear.
We hypothesize that not only pathogenic mutations, but 
also common variation on the promoter regions of SCN1A 
can interfere with normal expression. Although the effects 
of common variation are likely milder than those of a true 
pathogenic mutation in the promoter regions, a clinical ef-
fect might be detectable when common variation in the pro-
moter regions coexists with a pathogenic mutation in the 
coding region of SCN1A on the other allele. A small decrease 
in expression of SCN1A could lead to a decreased residual 
function of Nav1.1 in patients that are already haploinsuf-
ficient, and therefore lead to more severe clinical outcomes. 
Previously, no significant differences in expression were ob-
served for a group of common variants in the first SCN1A 
promoter region (Gao et al., 2017). We have cloned a new set 
of haplotypes and used a slightly altered promoter region that 
includes the first 5’ UE in the functional expression analysis. 
In this study, we analyze the first SCN1A promoter‐region 
of 143 participants affected by pathogenic SCN1A variants, 
to investigate whether common variation in this region can 
affect phenotypic outcomes.
2 |  MATERIALS AND METHODS
2.1 | Editorial policies and ethical 
considerations
The study was approved by the Ethical Committee of the 
University Medical Center Utrecht. Informed consent was 
obtained from participants or their legal caretakers according 
to the Declaration of Helsinki.
2.1.1 | Participants and clinical data
Participants
A cohort of 143 participants with SCN1A pathogenic variants 
was evaluated, of which most have previously been described 
(Lange, Gunning, et al., 2018; Lange, Koudijs, et al., 2018). 
Only participants with pathogenic variants (class V) or likely 
pathogenic variants (class IV) in SCN1A were included, ac-
cording to the American College of Medical Genetics and 
Genomics criteria (Richards et al., 2015). All variants had 
been detected and classified in genetic diagnostic laborato-
ries. Patients who had previously been shown to be mosaic 
(n = 4) for their pathogenic SCN1A variant were excluded 
from analyses, as mosaicism may greatly influence outcomes 
(Lange, Koudijs, et al., 2018). Our cohort comprised patients 
with Dravet syndrome, GEFS+, febrile seizures, and also 
four participants who had been seizure‐free their entire lives, 
but did have a child with Dravet syndrome that carried the 
same pathogenic SCN1A variant. Dravet syndrome was diag-
nosed based on previously published criteria (Verbeek et al., 
2013) and in line with recently published recommendations 
(Wirrell et al., 2017). Our main statistical analyses of clinical 
outcomes were performed on patients with Dravet syndrome 
only. Non‐Dravet syndrome patients remained included in 
the molecular analyses to separately investigate whether dif-
ferent promoter haplotypes could explain the inter‐familial 
phenotypic variability of Dravet syndrome patients and their 
more mildly affected family members.
Clinical data
Detailed clinical data were collected from medical records 
for all participants, and a semi‐structured telephone interview 
was conducted when possible (n = 130). A classification of 
the developmental outcome was made, rated in a consen-
sus meeting by a child neurologist, neuropsychologist, and 
clinical geneticist. Developmental outcome was rated on a 
five‐point scale based on available data on IQ and develop-
mental level (1 = no ID (IQ or developmental quotient (DQ) 
>85), 2 = borderline ID (IQ or DQ 70–85), 3 = mild ID (IQ 
or DQ 50–70), 4 = moderate ID (IQ or DQ 30–50), 5 = se-
vere or profound ID (IQ or DQ <30)). When no (recent) 
IQ or DQ was available, the assessment was made based 
on school functioning, communication and adaptive behav-
ior. Furthermore, approximated IQ/DQ scores after 5 years 
of disease were calculated, to obtain a cognitive outcome 
measurement unaffected by the influence of the different 
ages at assessment of the participants. For this, all IQ‐ and 
developmental assessment scores of each patient, conducted 
at different ages, were interpolated by linear regression as 
previously described (Lange, Gunning, et al., 2018). When 
the first official assessment was made later than 5 years after 
seizure onset we used the age at which a developmental delay 
was first observed (by either parents or clinicians) as the first 
moment of decline, and IQ/DQ scores up until that age were 
estimated to be average (=100).
2.1.2 | Molecular analyses
Functional characterization of common SCN1A promoter 
variants
The SCN1A (Homo sapiens chromosome 2, GRCh38.p12: 
166148836 to 166151403, NC_000002.12) promoter 1 re-
gion including h1u was PCR amplified from human con-
trol DNA using primers with a 15bp extension arm used for 
cloning. Five different haplotypes of 2568bp were selected 
and ligated in Psicheck‐2 plasmids using In‐Fusion cloning 
(clontech). The Psicheck‐2 plasmid enables dual‐reporter 
luciferase read‐out as it carries both the renilla (Renilla 
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reniformis derived) and firefly (Photinus pyralis derived) 
luciferase genes. Firefly luciferase is expressed by the HSV‐
TK promoter and can therefore be used as a control, while 
Renilla luciferase is controlled by the SCN1A promoter. As 
both genes are present on the same plasmid, unlike single 
reporter luciferase systems that require the transfection of 
two plasmids, the normalization and therefore read‐out is 
more accurate. Plasmids were subsequently sequenced to 
confirm the haplotypes. SH‐SY5Y cells were seeded in 24‐
well cell culture plates until 80% confluency was reached. 
Psicheck‐2 plasmids carrying the SCN1A promoter haplo-
types were transfected using polyethylenimine. After 48 hr, 
cells were lysed and the lysate transferred to a white opaque 
96‐well plate in which the luciferase recording took place. 
Firefly and Renilla luciferase activities were detected using 
the dual luciferase reporter assay system (Promega) in the 
Varioskan FLASH luminometer (Thermo Fisher Scientific). 
Read‐out was performed twice as a technical replicate, and 
averaged values were taken as final mean. Luciferase experi-
ments were replicated eight times. Differences in expression 
between haplotypes were not normally distributed and there-
fore analyzed using the Mann‐Whitney U‐test. For primer 
sequences see Supplementary Data S1.
Reconstruction of SCN1A promoter‐haplotypes of the 
unaffected allele in participants
SCN1A was re‐analysed in all participants as previously de-
scribed (Lange, Koudijs, et al., 2018). In short, all SCN1A 
exons were captured by single molecule molecular inver-
sion probes (smMIPs) and sequenced on a NextSeq500 
(Illumina, San Diego, CA). The resulting data were ana-
lyzed using commercial software (SeqNext module of 
Sequence Pilot; JSI medical systems, Ettenheim, Germany). 
Reads with the same single‐molecule tag were assembled 
into one consensus read, to correct for PCR and sequenc-
ing artefacts. SCN1A pseudogene reads were removed from 
alignment and analysis. The used smMIP design included 
the 5’ promoter region to capture three common promoter‐
variants (−1964 (rs2212657), −1036 (rs4319946) and −52 
(rs16851666)). The promoter‐haplotypes of the unaffected 
SCN1A allele of each patient was reconstructed based on the 
genotypes on these positions when possible. Direct assign-
ment of genotypes to the unaffected allele was only possible 
in the case of homozygous genotypes, when the same geno-
type is present on both alleles. In the case of heterozygous 
genotypes, assignment of genotypes to the affected and 
unaffected alleles was only possible if the following con-
dition was met: the participant had an affected family mem-
ber with a homozygous genotype at the same position, with 
whom they shared the same inherited pathogenic SCN1A 
variant. If so, the genotype present on the shared, affected 
allele is known and the genotype of the unaffected allele can 
be deducted. When the genotypes of the unaffected allele 
on all three positions could be reconstructed, one of the 
five described haplotypes could be matched and assigned. 
The frequency of the SCN1A promoter haplotypes in the 
non‐Finnish European population, which best resembles 
our cohort, was estimated by extracting these haplotypes 
from the 1,000 genomes Phase3 phased haplotype dataset 
(https ://mathg en.stats.ox.ac.uk/imput e/1000GP_Phase3.html), 
based on the −1964, −1036 and −52 SNPs.
Association of promoter variants with common epilepsies
A recent genome‐wide association study (GWAS) of 
the epilepsies identified a strong association with SNPs 
in SCN1A (The International League Against Epilepsy 
Consortium on Complex Epilepsies, 2018). We analyzed 
the association of the three common promoter variants with 
epilepsy using data from the latest epilepsy GWAS. We 
tested for independent associations of our promoter vari-
ants with epilepsy by performing a linear regression on 
each variant while conditioning on the most significant 
SCN1A‐SNP (rs6432877) from the GWAS. Conversely, 
we then tested to see if the GWAS association with SCN1A 
could be explained by our promoter SNPs by conditioning 
in the opposite direction.
Statistical analyses of clinical outcomes
Differences in clinical features and outcomes between 
Dravet syndrome patients with and without common vari-
ants in the SCN1A promoter‐region on their unaffected al-
lele were investigated. Ordinal regression, corrected for 
age, was used to investigate cognitive outcome scores; the 
Mann‐Whitney U test was used to investigate age at seizure 
onset, age at first notice of developmental delay, age at first 
afebrile seizure and interpolated IQ/DQ scores after 5 years 
of disease. A similar analysis was performed for Dravet 
syndrome patients with nonmosaic truncating pathogenic 
variants only, to limit the influence of different pathogenic 
SCN1A variants themselves on the results. All reported tests 
were performed two‐tailed with an alpha‐level for signifi-
cance of p < 0.05. We furthermore separately investigated 
whether family members, that carry the same pathogenic 
SCN1A variant but show varying disease severities, may 
have different promoter‐haplotypes that could explain their 
different outcomes.
3 |  RESULTS
3.1 | Functional characterization of 
common SCN1A promoter variants
Five different SCN1A promoter‐haplotypes were defined, 
based on eight SNPs in the −2,271 to 297 region (Figure 2). 
Haplotype 1 lacks all eight SNPs and was therefore regarded 
wild‐type, from which the relative SCN1A expression levels 
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were estimated for haplotypes 2–5. All non‐wildtype haplo-
types (2–5) showed a significant reduction in luciferase ex-
pression, compared to the wildtype promoter‐region (Figure 
2). The relative SCN1A expression decreased for 73% by 
haplotype 2, 64% by haplotype 3, 75% by haplotype 4, or 
haplotype 5).
3.2 | Reconstruction of SCN1A promoter‐
haplotypes of the unaffected allele in 
participants
SmMIP‐sequencing results were obtained for all partici-
pants. In all patients their known SCN1A pathogenic vari-
ant could be identified, except for variants undetectable by 
whole exome sequencing (e.g., deletions of the complete 
SCN1A gene), meaning no samples swaps had occurred. In 
46 patients the promoter variant genotype of their unaffected 
SCN1A allele could be reconstructed. All other patients had 
heterozygous genotypes at at least one of the three promoter 
variant locations, and had no included family members who 
could be used for haplotype phasing.
3.3 | Epilepsy‐GWAS associations of the 
common promoter variants
The strongest association with common epilepsy, which 
broadly comprises generalized and focal epilepsies, has been 
mapped to the SCN1A region in a recent GWAS of common 
epilepsy, with the most significantly associated SNP being 
rs6432877. The −52 and −1,036 promoter variants showed 
borderline genome wide significant with the “all epilepsy” 
phenotype, whereas the association of the −1964 variant 
was much weaker (p  =  6,20E−8, 1,00E−7 and 0.68 respec-
tively). In order to test whether the promoter variants were 
correlated to the SCN1A GWAS signal, we conditioned on 
the top GWAS SCN1A‐SNP (rs6432877) and observed 
that the associations were no longer significant indicating 
that these promoter variants SNPs are in variable Linkage 
Disequilibrium with the top GWAS SNP (r2 = 0.21, 0.63 and 
0.12 respectively). Conversely, we also tested to see if the 
signal from the top GWAS SCN1A‐SNP could be explained 
by one of the promoter variants by conditioning on each 
in turn. The strength of the GWAS signal diminished mar-
ginally when conditioning on the −52 and −1036 variants 
but was not affected by conditioning on the −1964 variant 
(pcond = 3.99E−08, 1.16E−05, and 1.12E−13, respectively), in-
dicating that the GWAS signal was not entirely dependent on 
the promoter variants.
3.4 | Clinical outcomes
Forty of the 46 participants with reconstructed promoter‐
haplotypes had been diagnosed with Dravet syndrome; the 
others had either GEFS+ syndrome or febrile seizures, 
and one participant had never experienced any seizures. 
Regarding the 40 Dravet syndrome patients: in nine pa-
tients a wildtype promoter‐region was detected (haplotype 
1); none of the patients carried haplotype 2; haplotype 3 
was identified in only one patient; haplotype 4 was pre-
sent in 12, and haplotype 5 was found in 18 participants. 
The estimated population frequency of the fivehaplotypes, 
based on the 1000genomes Phase3 phased haplotype 
dataset, was 0.232 for the haplotype 1, 0 for haplotype 2, 
0.0025 for haplotype 3, 0.3899 for haplotype 4, and 0.375 
for haplotype 5, which roughly resembles the distribution 
of haplotypes in our patients. An overview of the clinical 
outcomes of the 40 Dravet syndrome patients is shown in 
Table 1. No statistically significant differences were seen 
between patients with and without the common promoter 
variants (Table 1, Figures 3‒7). However, patients with a 
wildtype promoter‐haplotype on their unaffected SCN1A 
F I G U R E  2  Functional effect of common promoter variants 
in SCN1A. Top: Simplified SCN1A 5’ UTR, adapted from Figure 1. 
Middle: Promoter haplotypes tested in this study. Haplotype 1 depicts 
a promoter + h1u region without common variants. Haplotype 2, 3, 
4 and 5 carry multiple common variants spread over the promoter 
region: −1964 (rs2212657, MAF 0.43), −1663 (rs151217464, MAF 
0.01), −1449 (rs7606233, MAF 0.50), −1036 (rs4319946, MAF 0.49), 
−688 (rs16851669, MAF 0.50), −244 (rs80169419, MAF 0.07), −52 
(rs16851666, MAF 0.50) and 34 (rs757291646, MAF < 0.01). Bottom: 
Luciferase expression analysis of SCN1A promoter haplotypes as 
depicted above. Empty vector (SV40) expression was set to 100%. 
Haplotype 1, without common variants was used as control haplotype 
of which the expression reduction of Haplotype 2, 3, 4 and 5 was 
measured
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allele showed a nonsignificant trend for milder pheno-
types, when compared to patients that carried a variant 
promoter haplotype: on average, seizure onsets occurred 
at an older age (6.1 vs. 5.1  months, p  =  0.746), as did 
developmental delays (median 36–47 months vs. median 
24–35 months, p = 0.265). Furthermore, cognitive capac-
ities declined slower (IQ after 5  years of disease 73 vs. 
65.9, p = 0.566). More favorable cognitive outcome scores 
were also observed, although this is likely to be at least 
partly due to the wildtype‐patients being younger than the 
other group. Similar outcomes were seen for Dravet syn-
drome patients with truncating variants only (Table 2): al-
though this group consisted of only 19 patients, leading to 
a lower detection power, a similar nonsignificant trend for 
milder phenotypes was observed in patients with wildtype 
promoters.
3.5 | Anecdotal family studies
Among the complete group of 46 participants with recon-
structed promoter‐haplotypes were eight participants, belong-
ing to four different families that showed a clear intra‐familial 
variability (Figure 8): family 1 consists of a severely affected 
10‐year‐old proband with Dravet syndrome, and a father with 
mild epilepsy and normal cognitive functioning. Family 2 
consists of two brothers with Dravet syndrome, one of whom 
is more severely affected than the other. Family 3 consists of 
a proband with a phenotype on the border of Dravet syndrome 
T A B L E  1  Clinical outcomes of patients with different promoter‐haplotypes (all nonmosaic Dravet syndrome patients)
Promoter‐haplotype 
unaffected allelea 1 3 4 5
Any variant  
(haplotype 3, 4 or 5) p‐value (test)e
Number of patients 9 1 12 18 31  
Age (years, mean/
median)
12/7 14/14 14/13 16/14 15/13  
Cognitive outcomeb 
(median)
3 5 4 4 4 0.859 (Ordinal re-
gression corrected 
for age)
Age at seizure onset 
(months, mean)
6.1 (missing: 1) 5.0 5.7 5.2 5.4 0.746 (MWU test)
Age at first notice of 
developmental delayc 
(median)
3 (missing: 1) 1 2 (missing: 1) 2 2 (missing: 1) 0.265 (MWU test)
Age at first afebrile 
seizured (median)
0 (missing: 1) 0 0 (missing: 1) 0 (missing: 2) 0 (missing: 3) 0.837 (MWU test)
Interpolated IQ/DQ 
score after 5 years of 
disease (mean)
73.0 (missing: 3) 33.0 64.5 (missing: 5) 68.9 (missing: 4) 65.9 (missing: 9) 0.566 (MWU test)
a1: Wildtype (no variants). 2: variant at −52. 3: variant at −1964. 4: variant at −52 and −1964. 5: variant at −1964 and −1036. 
bBased on available data on IQ and developmental level, adjusted for age at assessment (1 = no ID (IQ or developmental quotient (DQ) >85), 2 = borderline ID (IQ 
or DQ 70–85), 3 = mild ID (IQ or DQ 50–70), 4 = moderate ID (IQ or DQ 30–50), 5 = severe or profound ID (IQ or DQ <30)). When no (recent) IQ or DQ was 
available, the assessment was made based on school functioning, communication and adaptive behavior. 
cBy parents or physicians. 0 = <12 months, 1 = 12–23 months, 2 = 24–35 months, 3 = 36–47 months, 4 = >48 months, 5 = no developmental delay. 
d0 = <12 months, 1 = 12–23 months, 2 = 24–47 months, 3 = >48 months, 4 = never had afebrile seizures. 
ep‐values are based on statistical analyses of differences between group 1 (wiltype) and all other haplotypes combined (any variant). All reported tests were performed 
two‐tailed with an alpha‐level for significance of p < 0.05. MWU‐test = Mann Whitney U‐test. 
F I G U R E  3  distribution of different cognitive outcome scores 
between patients with and without variants in the promoter‐region of 
their unaffected SCN1A allele
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and GEFS+, with regression over the years. His father has 
never had any seizures. Family 4 consists of two brothers of 
whom the oldest has severe Dravet syndrome and the young-
est has a much milder phenotype. In family 2, 3 and 4, each 
of the milder participants carried haplotype 5, and each of 
the more severely affected participants carried haplotype 4. 
Since only very small, insignificant differences in luciferase 
expression between haplotype 4 and 5 were observed, the dif-
ferent promoter‐haplotypes are unlikely to explain the clini-
cal differences between these patients. However, in family 
1, the severely affected patient carried haplotype 5, whereas 
the milder patient had a wildtype promoter, for which we did 
observe a large difference in luciferase expression.
4 |  DISCUSSION
Our experiments showed that the presence of common vari-
ants in the promoter‐region of SCN1A cause a significant 
decrease in luciferase activity, compared to the wildtype 
promoter. This indicates that SCN1A expression and func-
tion may be negatively influenced by such variants, likely 
due to disturbance of RNA polymerase II and/or transcrip-
tion factor binding. Although this reduced expression can-
not cause epilepsy independently, since a large part of the 
healthy populations carries these common variants as well, 
it may modulate the effect of other variants that are present. 
Our results can only in part be compared to those of Gao et 
al. (Huang et al., 2014), who found no differences in expres-
sion between the most common promoter‐haplotypes. These 
different results may be attributed to three factors. First, we 
are measuring a different group of variants, which results in 
different expression levels. Second, we have cloned a slightly 
altered promoter region that is shorter on the 5’ side, but ex-
tended on the 3’ side to include the complete h1u. H1u, the 
first 5’ UE contains transcription factor binding sites such 
as EBF and the Initiator element that is required to form the 
transcription complex. Third, we use the Promega dual‐assay 
luciferase plasmid, which has both the renilla and firefly lu-
ciferase gene incorporated. In single‐assay luciferase assays, 
using two plasmids, normalization of luciferase data could 
be less sensitive. In general, the luciferase reporter assay is 
currently the fastest tool to measure gene expression at the 
transcriptional level. Nevertheless, it should be noted that 
in vitro assays can never fully mimic an in vivo state, espe-
cially in complex structures such as the brain. While for this 
study a neuronal cell line was used to perform the expression 
studies, this can be improved by introducing the luciferase 
constructs in the brain of an animal model. In this way, the 
interactions between cell types in the brain are included, ap-
proaching the in vivo state more accurately. Also, SCN1A has 
at least three promoters which are consecutively active and 
five 5’ UE's currently known, adding up to the difficulty of 
interpreting SCN1A expression. Nevertheless, we found that 
a combination of common and rare variants in the SCN1A 
promoter 1region, reduced expression on transcription level. 
The reduced luciferase expression was in line with our hy-
pothesis that a set of SCN1A variants may affect expression 
of the gene and thus lead to more severe phenotypes, when 
present on the unaffected SCN1A allele of a Dravet syndrome 
patient. However, the clinical consequences of these differ-
ent haplotypes were less convincing: no statistically signifi-
cant differences were seen between patients with and without 
the common promoter variants, although we did observe a 
minor trend of more severe outcomes on multiple clinical 
F I G U R E  4  distribution of age at seizure onset between patients 
with and without variants in the promoter‐region of their unaffected 
SCN1A allele
F I G U R E  5  distribution of onset of developmental delay between 
patients with and without variants in the promoter‐region of their 
unaffected SCN1A allele
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variables in patients with common promoter variants. There 
may be several reasons for this. First, it is likely that common 
variants in the promoter region only have small phenotypic 
effects, since they otherwise would have been subject to 
negative selection. This limited effect was also illustrated 
by Gao et al., (2017); although a pathogenic point mutation 
in the SCN1A promoter‐region led to an in vitro decrease of 
F I G U R E  6  distribution of age at first afebrile seizure between 
patients with and without variants in the promoter‐region of their 
unaffected SCN1A allele
F I G U R E  7  distribution of IQ/DQ scores after five years of 
disease between patients with and without variants in the promoter‐
region of their unaffected SCN1A allele
T A B L E  2  Clinical outcomes of patients with different promoter‐haplotypes (non‐mosaic Dravet syndrome patients with truncating SCN1A 
variants)
Promoter‐haplotype 
unaffected allelea 1 3 4 5
Any variant  
(haplotype 3, 4 or 5) p‐value (test)e
Number of patients 5 1 5 8 14  
Age (years, mean/
median)
14/7 14/14 11/13 22/24 17.3/14.5  
Cognitive outcomeb 
(median)
3 5 4 4.5 4 0.547 (Multiple re-
gression corrected 
for age)
Age at seizure onset 
(months, mean)
6.6 5.0 6.0 5.25 5.5 0.823 (MWU test)
Age at first notice of 
developmental delayc 
(median)
4 1 2 2.5 2 0.298 (MWU test)
Age at first afebrile 
seizured (median)
0 0 0 0 (missing: 2) 0 (missing: 2) 0.712 (MWU test)
Interpolated IQ/DQ 
score after 5 years of 
disease (mean)
75.1 (missing: 2) 33.0 65.7 (missing: 3) 74.9 (missing: 1) 68.9 (missing: 4) 0.973 (MWU test)
a1: Wildtype (no variants). 2: variant at −52. 3: variant at −1964. 4: variant at −52 and −1964. 5: variant at −1964 and −1036. 
bBased on available data on IQ and developmental level, adjusted for age at assessment (1 = no ID (IQ or developmental quotient (DQ) >85), 2 = borderline ID (IQ 
or DQ 70–85), 3 = mild ID (IQ or DQ 50–70), 4 = moderate ID (IQ or DQ 30–50), 5 = severe or profound ID (IQ or DQ <30). When no (recent) IQ or DQ was avail-
able, the assessment was made based on school functioning, communication, and adaptive behavior. 
cBy parents or physicians. 0 = <12 months, 1 = 12–23 months, 2 = 24–35 months, 3 = 36–47 months, 4 = >48 months, 5 = no developmental delay. 
d0 = <12 months, 1 = 12–23 months, 2 = 24–47 months, 3 = >48 months, 4 = never had afebrile seizures. 
ep‐values are based on statistical analyses of differences between group 1 (wiltype) and all other haplotypes combined (any variant). All reported tests were performed 
two‐tailed with an alpha‐level for significance of p < 0.05. MWU‐test = Mann Whitney U‐test. 
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expression and mild epilepsy in a proband, the same variant 
was found in the asymptomatic mother of the patient. This in-
dicates that promoter‐variants by themselves may only have 
a limited influence on phenotypes. To detect such small ef-
fects, large sample sizes are prerequisite. Our study sample 
is likely too small to reliably detect any phenotypic conse-
quences. Second, other (stronger) modifiers may simultane-
ously modulate the effect of promoter‐variants. Although we 
excluded patients with mosaic pathogenic variants, we can-
not eliminate the influence of variants in modifier genes and 
environmental factors on outcomes. If these other factors are 
strong influencers, they may override any effects the pro-
moter‐variants have.
Besides a small sample size, our study has several other 
limitations. While the luciferase plasmids were fully se-
quenced, the SCN1A patient promoter haplotypes were re-
constructed based on three common SNPs. No sequencing 
of the complete promoter‐region was performed in the par-
ticipants. The patients’ haplotypes may therefore not fully 
correspond to the haplotypes tested during the luciferase ex-
periments. Theoretically, patients may harbor additional pro-
moter‐variants that could either rescue or aggravate impaired 
expression. This could have large effects on outcomes in a 
sample size as small as ours. Furthermore, different primary 
pathogenic SCN1A variants may influence outcomes; how-
ever, a trend for milder phenotypes in patients with wildtype 
promoters was seen for the group of patients with truncat-
ing mutations only as well, which indicates that this effect is 
limited.
We also analyzed four families of which multiple mem-
bers were affected by the same pathogenic SCN1A vari-
ant, but showed different phenotypes nonetheless; in these 
cases the effect of the primary mutation on the resulting 
phenotype is expected to be equal. Since in three of the four 
families both members had variant‐haplotypes, our hypoth-
esis could not explain their phenotypic differences. This is 
however not surprising, since in two of these families both 
members were affected by different clinical syndromes; as 
stated before, the modifying effect of promoter‐variants 
is likely not strong enough to cause this independently. In 
only one family, consisting of two brothers with Dravet 
syndrome, the milder brother carried a wildtype promoter 
on his unaffected allele, whereas the more severe brother 
carried a variant‐promoter. According to our hypothesis, 
this might explain their phenotypic differences; however, 
as mentioned previously, we cannot exclude other influ-
encers and definitive conclusions are not possible based on 
only one family.
In conclusion, we found that common variants in the 
SCN1A promoter reduce transcription in neuronal cell cul-
ture, which may indicate that promoter haplotypes can act 
as a disease modifier in epilepsy. We however only found a 
small, nonsignificant effect of the SCN1A promoter on clini-
cal outcomes of Dravet syndrome patients. These results are 
inconclusive due to a limited detection power; however, the 
observed trends in our cohort warrant replication studies in 
larger cohorts to explore the potential modifying role of these 
common SCN1A promoter‐haplotypes. The inclusion of 
large numbers of Dravet syndrome patients, ideally all with 
similar primary LoF variants, is essential to detect the likely 
small effect these haplotypes might have on phenotypes. 
Sequencing of all three complete SCN1A promoter‐regions, 
preferably including the 5’‐UEs, would be required to obtain 
conclusive results.
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